Developer docs
API playgroundTry for free, no card

Search company profiles

Orlance

Full company profile

uuid0003f12

Namestring
Orlance
Legal namestring
Orlance, Inc.
Websiteurl
orlance.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Orlance, Inc. is a Seattle-based, preclinical-stage biotechnology company developing the MACH-1 platform, a needle-free vaccine delivery system that deposits dry, stable RNA-coated gold microparticles directly into skin immune cells — specifically Langerhans cells and dermal dendritic cells — for DNA and RNA vaccine administration. The company's product portfolio is anchored on this single core platform technology, with pipeline candidates including a universal influenza vaccine and a melanoma cancer immunotherapy vaccine, both aimed at Phase 1 clinical trials.

The company is pre-revenue and has been funded entirely through non-dilutive NIH SBIR grants totaling approximately $3.6 million across 2023 and 2024, supporting platform optimization and candidate vaccine development. Its intended go-to-market model is B2B licensing of the MACH-1 platform to pharmaceutical partners for co-development in infectious disease and oncology, with stated end-customers including public health organizations (for pandemic preparedness) and pharmaceutical companies seeking advanced vaccine delivery technologies. Founded in 2016, Orlance operates with 1–10 employees and has no disclosed commercial customers, partnerships outside of NIH/NIAID, or revenue-generating activities.

Short descriptiontext

Orlance is a Seattle-based preclinical biotech developing the MACH-1 needle-free vaccine delivery platform, which uses dry RNA-coated gold microparticles to target skin immune cells. It is building pipeline candidates in universal influenza and melanoma immunotherapy, funded by NIH SBIR grants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
needle-free vaccine delivery, RNA vaccine platform, DNA vaccine technology, cancer immunotherapy vaccines, infectious disease vaccines
Industry4 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biotechnology / Vaccine Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Platform Licensing
TypeLicensing Royalties
Description

Pre-revenue biotech company currently funded through NIH SBIR grants. Expected revenue model involves licensing the MACH-1 platform technology to pharmaceutical partners for vaccine development in infectious diseases and cancer immunotherapy.

prnewswire.com
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MACH-1
Description

Needle-free vaccine delivery platform that delivers dry, stable RNA-coated gold microparticles into the skin for improved vaccine safety, stability, and efficacy.

prnewswire.com
Core offering1 text field

Orlance develops the MACH-1 needle-free vaccine delivery platform, which uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells without needles. The company is advancing pipeline vaccine candidates built on this platform, including a melanoma cancer immunotherapy vaccine and a universal influenza vaccine, with the goal of moving toward Phase 1 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • NIH validation through multiple SBIR grants totaling $3.6 million supporting platform development toward Phase 1 clinical trials
Product overview1 text field

Orlance is a Seattle-based biotech company developing a single unified technology platform called MACH-1, a needle-free delivery system for RNA and DNA vaccines. The platform delivers dry, stable RNA-coated gold microparticles directly into skin immune cells. The company's product portfolio centers on this core platform technology, with pipeline products including a melanoma vaccine candidate and a universal influenza vaccine, both currently in development with NIH SBIR grant funding toward Phase 1 clinical trials.

Product and service3 records
1MACH-1 Platform
CategoryVaccine delivery platform / Core technology
Description

Needle-free vaccine delivery platform that uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells (Langerhans cells and dermal dendritic cells) for improved safety, stability, and efficacy. The platform is intended to be licensed to pharmaceutical and biotech partners for vaccine development in infectious diseases and cancer immunotherapy.

2Melanoma Vaccine Candidate
CategoryOncology vaccine candidate
Description

DNA and RNA vaccine delivered via the MACH-1 platform into skin immune cells for cancer immunotherapy targeting melanoma. A pipeline development candidate, currently pre-clinical and funded by NIH SBIR grant support.

3Universal Influenza Vaccine
CategoryInfectious disease vaccine candidate
Description

Broad-immunity influenza vaccine candidate built on the MACH-1 needle-free platform, designed to overcome the limitations of current seasonal flu vaccines and provide protection against future pandemic influenza strains. Currently pre-clinical and advancing toward Phase 1 clinical trials.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Developer of high-density microarray patch (HD-MAP) technology for needle-free vaccine delivery into the skin. Highly comparable on needle-free skin-delivery mechanism and vaccine application, though Vaxxas focuses on patch-format delivery rather than particle-based deposition.

TypeDirect peer
Description

Needle-free jet injection technology company whose Tropis and Stratis devices deliver vaccines and therapeutics intradermally or intramuscularly without needles. Most directly comparable on the delivery-mechanism axis that defines Orlance's MACH-1 platform.

TypeDirect peer
Description

Clinical-stage DNA vaccine company with proprietary CELLECTRA intradermal electroporation delivery. Comparable because both target skin immune cells for DNA/RNA vaccines against infectious disease and cancer (including HPV-related and oncology indications).

TypeBroad incumbent
Description

Dominant mRNA vaccine platform company. Directly comparable because both Moderna and Orlance develop RNA/DNA vaccines, though Moderna operates at vastly greater scale and focuses on lipid nanoparticle delivery rather than needle-free skin delivery.

TypeBroad incumbent
Description

Leading mRNA therapeutics company and Pfizer's COVID-19 vaccine partner. Comparable in RNA vaccine modality and infectious-disease/cancer-immunotherapy pipeline focus; differs in delivery technology and scale.

TypeEmerging player
Description

Developer of dissolvable microneedle array patches for vaccine and drug delivery. Comparable as a needle-free, skin-targeted vaccine delivery company; partial overlap given different delivery format (dissolvable arrays vs. gold microparticles).

TypeDirect peer
Description

mRNA technology platform company developing prophylactic and therapeutic vaccines. Comparable in RNA platform breadth and infectious-disease focus; Orlance's differentiator is delivery and formulation rather than mRNA chemistry.

TypeBroad incumbent
Description

Major influenza vaccine manufacturer actively pursuing universal and next-generation flu vaccines. Comparable because Orlance's universal influenza program directly competes in this category, and CSL Seqirus is a likely target partner or competitor.

TypeBroad incumbent
Description

Global vaccines leader with the Comirnaty mRNA franchise and broad infectious-disease and oncology pipelines. Relevant as both a potential licensing partner for MACH-1 and as the dominant incumbent whose RNA vaccine delivery Orlance seeks to differentiate from.

10Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines division developing mRNA, protein subunit, and next-generation influenza and infectious-disease vaccines. Comparable as both a potential licensing/copromotion partner and a strategic competitor pursuing needle-free and intradermal delivery internally.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orlance

Biotechnology / Vaccine Developmentorlance.com

Orlance is a Seattle-based preclinical biotech developing the MACH-1 needle-free vaccine delivery platform, which uses dry RNA-coated gold microparticles to target skin immune cells. It is building pipeline candidates in universal influenza and melanoma immunotherapy, funded by NIH SBIR grants.

What Orlance does

Orlance, Inc. is a Seattle-based, preclinical-stage biotechnology company developing the MACH-1 platform, a needle-free vaccine delivery system that deposits dry, stable RNA-coated gold microparticles directly into skin immune cells — specifically Langerhans cells and dermal dendritic cells — for DNA and RNA vaccine administration. The company's product portfolio is anchored on this single core platform technology, with pipeline candidates including a universal influenza vaccine and a melanoma cancer immunotherapy vaccine, both aimed at Phase 1 clinical trials.

The company is pre-revenue and has been funded entirely through non-dilutive NIH SBIR grants totaling approximately $3.6 million across 2023 and 2024, supporting platform optimization and candidate vaccine development. Its intended go-to-market model is B2B licensing of the MACH-1 platform to pharmaceutical partners for co-development in infectious disease and oncology, with stated end-customers including public health organizations (for pandemic preparedness) and pharmaceutical companies seeking advanced vaccine delivery technologies. Founded in 2016, Orlance operates with 1–10 employees and has no disclosed commercial customers, partnerships outside of NIH/NIAID, or revenue-generating activities.

Orlance firmographics

Firmographics
Name
Orlance
Legal name
Orlance, Inc.
Website
https://orlance.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Orlance is a Seattle-based preclinical biotech developing the MACH-1 needle-free vaccine delivery platform, which uses dry RNA-coated gold microparticles to target skin immune cells. It is building pipeline candidates in universal influenza and melanoma immunotherapy, funded by NIH SBIR grants.
Ownership category
akta.pro rank

Orlance industry classification

Industry
Product category
Biotechnology / Vaccine Development
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Needle-free vaccine delivery
  • RNA vaccine platform
  • DNA vaccine technology
  • Cancer immunotherapy vaccines
  • Infectious disease vaccines

Where Orlance is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orlance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Vaccine Platform Licensing: Pre-revenue biotech company currently funded through NIH SBIR grants. Expected revenue model involves licensing the MACH-1 platform technology to pharmaceutical partners for vaccine development in infectious diseases and cancer immunotherapy.

Go-to-market motion1 record

Orlance product offering

Product offering

Core offering

Orlance develops the MACH-1 needle-free vaccine delivery platform, which uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells without needles. The company is advancing pipeline vaccine candidates built on this platform, including a melanoma cancer immunotherapy vaccine and a universal influenza vaccine, with the goal of moving toward Phase 1 clinical trials.

Product overview

Orlance is a Seattle-based biotech company developing a single unified technology platform called MACH-1, a needle-free delivery system for RNA and DNA vaccines. The platform delivers dry, stable RNA-coated gold microparticles directly into skin immune cells. The company's product portfolio centers on this core platform technology, with pipeline products including a melanoma vaccine candidate and a universal influenza vaccine, both currently in development with NIH SBIR grant funding toward Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • MACH-1: Needle-free vaccine delivery platform that delivers dry, stable RNA-coated gold microparticles into the skin for improved vaccine safety, stability, and efficacy.

Products and services

  • MACH-1 Platform Needle-free vaccine delivery platform that uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells (Langerhans cells and dermal dendritic cells) for improved safety, stability, and efficacy. The platform is intended to be licensed to pharmaceutical and biotech partners for vaccine development in infectious diseases and cancer immunotherapy.
  • Melanoma Vaccine Candidate DNA and RNA vaccine delivered via the MACH-1 platform into skin immune cells for cancer immunotherapy targeting melanoma. A pipeline development candidate, currently pre-clinical and funded by NIH SBIR grant support.
  • Universal Influenza Vaccine Broad-immunity influenza vaccine candidate built on the MACH-1 needle-free platform, designed to overcome the limitations of current seasonal flu vaccines and provide protection against future pandemic influenza strains. Currently pre-clinical and advancing toward Phase 1 clinical trials.

Quantifiable outcome

  • NIH validation through multiple SBIR grants totaling $3.6 million supporting platform development toward Phase 1 clinical trials

Companies that use Orlance

Customer profile

Segments2 records

Ideal customer profiles2 records

Orlance technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Orlance partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Orlance competitors and assessment

Company assessment

Emerging players

  • Vaxxas: Developer of high-density microarray patch (HD-MAP) technology for needle-free vaccine delivery into the skin. Highly comparable on needle-free skin-delivery mechanism and vaccine application, though Vaxxas focuses on patch-format delivery rather than particle-based deposition.
  • Micron Biomedical: Developer of dissolvable microneedle array patches for vaccine and drug delivery. Comparable as a needle-free, skin-targeted vaccine delivery company; partial overlap given different delivery format (dissolvable arrays vs. gold microparticles).

Direct peers

  • PharmaJet: Needle-free jet injection technology company whose Tropis and Stratis devices deliver vaccines and therapeutics intradermally or intramuscularly without needles. Most directly comparable on the delivery-mechanism axis that defines Orlance's MACH-1 platform.
  • Inovio Pharmaceuticals: Clinical-stage DNA vaccine company with proprietary CELLECTRA intradermal electroporation delivery. Comparable because both target skin immune cells for DNA/RNA vaccines against infectious disease and cancer (including HPV-related and oncology indications).
  • CureVac: mRNA technology platform company developing prophylactic and therapeutic vaccines. Comparable in RNA platform breadth and infectious-disease focus; Orlance's differentiator is delivery and formulation rather than mRNA chemistry.

Broad incumbents

  • Moderna: Dominant mRNA vaccine platform company. Directly comparable because both Moderna and Orlance develop RNA/DNA vaccines, though Moderna operates at vastly greater scale and focuses on lipid nanoparticle delivery rather than needle-free skin delivery.
  • BioNTech: Leading mRNA therapeutics company and Pfizer's COVID-19 vaccine partner. Comparable in RNA vaccine modality and infectious-disease/cancer-immunotherapy pipeline focus; differs in delivery technology and scale.
  • CSL Seqirus: Major influenza vaccine manufacturer actively pursuing universal and next-generation flu vaccines. Comparable because Orlance's universal influenza program directly competes in this category, and CSL Seqirus is a likely target partner or competitor.
  • Pfizer: Global vaccines leader with the Comirnaty mRNA franchise and broad infectious-disease and oncology pipelines. Relevant as both a potential licensing partner for MACH-1 and as the dominant incumbent whose RNA vaccine delivery Orlance seeks to differentiate from.
  • Sanofi Pasteur: Global vaccines division developing mRNA, protein subunit, and next-generation influenza and infectious-disease vaccines. Comparable as both a potential licensing/copromotion partner and a strategic competitor pursuing needle-free and intradermal delivery internally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Orlance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orlance leadership team

Management profile

Number of profiles

Orlance funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orlance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orlance

What does Orlance do?

Orlance develops the MACH-1 needle-free vaccine delivery platform, which uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells without needles. The company is advancing pipeline vaccine candidates built on this platform, including a melanoma cancer immunotherapy vaccine and a universal influenza vaccine, with the goal of moving toward Phase 1 clinical trials.

Is Orlance a public or private company?

Orlance is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Orlance founded?

Orlance was founded in 2016. It employs 1 to 10 people.

Where is Orlance based?

Orlance is headquartered in Seattle, United States, in the North America region.

How does Orlance make money?

One revenue line is on record: vaccine Platform Licensing.

Who are Orlance's main competitors?

Emerging players on record are Vaxxas and Micron Biomedical. Direct peers are PharmaJet, Inovio Pharmaceuticals and CureVac. Broad incumbents are Moderna, BioNTech, CSL Seqirus, Pfizer and Sanofi Pasteur.

Does Orlance have an API?

No public API is recorded for Orlance.

What industry is Orlance in?

Orlance's product category is Biotechnology / Vaccine Development. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOrlance, Inc. awarded RNA Vaccine Development GrantSeattle-based biotech Orlance, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop RNA vaccine formulations using its MACH-1 needle-free delivery platform. The two-year grant provides $600,000 total funding to optimize RNA stability and efficacy for infectious diseases and cancer immunotherapy applications. This development supports Orlance's goal of initiating clinical trials for its lead asset in 2025.OrlanceOrlance Press ReleasesOrlance, Inc. has been awarded a $600,000 Phase I STTR grant from the National Institutes of Health (NIH) to develop a therapeutic vaccine for chronic Hepatitis B using its MACH-1 platform. The project intends to optimize DNA vaccine delivery for individuals co-infected with HIV and HBV, aiming to improve chronic infection outcomes that currently lack effective treatment options.PR NewswireOrlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1™ Needle-Free, Powdered Universal Influenza Vaccine to the ClinicOrlance Inc. has been awarded a $3 million NIH SBIR grant to advance its MACH-1 needle-free delivery platform and universal influenza vaccine toward Phase 1 clinical trials. This funding supports formulation and preclinical validation activities aimed at creating a stable, broad-spectrum flu vaccine that does not require annual updates. The company plans to initiate these clinical trials in 2025.BioSpaceOrlance Inc. Awarded NIH SBIR Grant for Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for MelanomaOrlance Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health to develop next-generation DNA and RNA immunotherapeutic vaccines for melanoma using its MACH-1 gene-gun platform. The funding supports preclinical development aimed at creating needle-free, stable vaccine candidates that induce strong tumor-specific immune responses. This award brings Orlance's total SBIR funding to $12.9 million as it advances toward IND readiness for potential clinical trials.BioSpaceOrlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1™ Needle-Free, Powdered Universal Influenza Vaccine to the ClinicOrlance Inc. has been awarded a $3 million Phase II SBIR grant from the National Institutes of Health to advance its MACH-1 needle-free delivery platform and universal influenza vaccine toward Phase 1 clinical trials. This funding supports formulation and preclinical validation activities, bringing Orlance's total SBIR funding to $12.5 million for its next-generation DNA and RNA vaccine development. The company plans to initiate these clinical trials in 2025.PR NewswireOrlance Inc. Awarded NIH SBIR Grant for Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for MelanomaOrlance Inc., a Seattle-based biotech company, has been awarded a National Institutes of Health (NIH) Phase I Small Business Innovation Research (SBIR) grant to develop a needle-free melanoma vaccine using its MACH-1 gene-gun technology platform that delivers DNA or RNA vaccine-coated microparticles directly into skin cells. The MACH-1 platform offers advantages over current mRNA vaccines including room temperature stability, painless needle-free delivery, and the ability to trigger protective immunity at lower doses. The grant will fund proof-of-concept, formulation, and adjuvant incorporation work to advance lead candidates toward IND readiness, bringing Orlance's total SBIR funding to $12.9 million, with the company planning to initiate Phase 1 clinical trials for its lead infectious disease asset in 2025.